Apalcillin is a naphthyridine derivative of ampicillin. It has a broad spectrum of antibacterial activity, including activity against Pseudomonas aeruginosa (1, (4) (5) (6) (7) (8) . The present report compares apalcillin with piperacillin and carbenicillin against all bacterial isolates that were selected for antimicrobial susceptibility testing in four separate institutions over a 45-to 60-day period. Three laboratories utilized broth microdilution tests, and one utilized agar dilution tests; all followed the procedures outlined by the National Committee for Clinical Laboratory Standards (3) . Standard quality control strains (Staphylococcus aureus ATCC 29213, Streptococcus faecalis ATCC 29212, Escherichia coli ATCC 25922, P. aeruginosa ATCC 27853) were tested in each laboratory throughout the study period (Table 1 ). All four institutions provided essentially identical MICs for the control strains. Among those species with enough strains to warrant comparisons between laboratories, MICs required to inhibit 50% of strains (MIC50s) were identical in all four laboratories. Consequently, the data were combined for presentation in this report.
During the study period, tests were performed with 3,452 members of the family Enterobacteriaceae, 983 nonenteric gram-negative bacilli, 1,060 streptococci, and 1,032 staphylococci. These isolates are representative of the types of microorganisms normally encountered in the participating laboratories.
Data accumulated with the Enterobacteriaceae are summarized in Table 2 . Apalcillin was essentially as effective as piperacillin against most species. However, the Serratia marcescens isolates were generally more susceptible to piperacillin than to apalcillin (MIC5os, 2.0 and 8.0 ,Lg/ml, respectively). At 64 ,ug/ml, both drugs inhibited 97.5% of the Serratia marcescens isolates. Only 73% of the Enterobacteriaceae were susceptible to carbenicillin (MIC, <128 ,ug/ml), whereas 92% were susceptible to apalcillin and piperacillin (MIC,crs64 png/ml). * Corresponding author. Table 3 summarizes data with nonenteric gram-negative bacilli and streptococci. Apalcillin was significantly more active than piperacillin against P. aeruginosa (MIC90s, 8 .0 versus 64 ,ug/ml; MIC50s, 2.0 versus 4.0 pLg/ml) and against Acinetobacter calcoaceticus subsp. anitratus (MIC90s, 8 .0 versus 64 ,ug/ml; MIC50s, 2.0 versus 16 ,ug/ml). Among the P. aeruginosa isolates, 11.5% were resistant to carbenicillin (MIC, >128 ,ug/ml), 5.3% were resistant to piperacillin (MIC, >64 ,ug/ml), and only 0.7% were resistant to apalcillin (MIC, >64 ,uglml). Apalcillin also demonstrated superior activity against Pseudomonas maltophilia (MIC50, 8.0 ,ug/ ml; MIC90, 64 ,ug/ml).
Against the streptococci, apalcillin and piperacillin demonstrated comparable activities. Both drugs inhibited the Streptococcus faecalis isolates (MIC90, 4.0 pg/ml for both drugs), but carbenicillin was much less effective (MIC90, 128 ,g/ml). Additional tests were performed with 862 Staphylococcus aureus isolates and 440 coagulase-negative staphylococci (data not shown). 3-Lactamase-producing strains were all more resistant to each penicillin, compared with non-3-lactamase-producing strains. Apalcillin, piperacillin, and carbenicillin should not be considered antistaphylococcal drugs since they are inactivated by staphylococcal ,-lactamase.
Additional agar dilution MIC data with 166 anaerobic bacteria were obtained by one of the participating laboratories (Table 4 Pharmacokinetic properties of apalcillin differ from those of piperacillin (2) . Apalcillin has a longer half-life and is excreted primarily by way of nonrenal routes (mainly hepatic clearance) (2) . Whether these pharmacokinetic properties offer a therapeutic advantage remains to be seen. The increased activity of apalcillin against P. aeruginosa and Acinetobacter spp. should offer a significant advantage over piperacillin. 
